Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | March 31, 2015 | April 02, 2015 |
| MBX Biosciences, Inc.MBX · Entity 4247 | Director | June 05, 2025 | June 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 31, 2015 · Filed April 02, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 79,851 |
Reported balance
After 2015-03-31 transaction · row 1
1 source rowRow 1 · 2015-03-31 · Grant · Acquired 387 · Balance 79,851 F1: Shares awarded to Mr. Cornelius for service as Non-Executive Chairman. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares awarded to Mr. Cornelius for service as Non-Executive Chairman.
MBX Biosciences, Inc.
Report date June 05, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.86 · Expires 2035-06-05 | Direct | 16,000 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 16,000 · Balance 16,000 F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mead Johnson Nutrition Co
Report date June 15, 2017 · Filed June 15, 2017
Section 16 reporting ended · disclosed 2017-06-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-06-15 transaction · row 1
1 source rowRow 1 · 2017-06-15 · Disposition to issuer · Disposed 55,244 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy 2015 Grantor Retained Annuity Trust | 0 |
Reported balance
After 2017-06-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-06-15 · Disposition to issuer · Disposed 27,975 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-06-15 · Disposition to issuer · Disposed 3,418 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock. F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock.
F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2025 Filed Jun 6, 2025 12:04 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock option (right to buy) · Derivative | 16,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0000950170-25-082702 · ownership.xml · derivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:11 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries B Convertible Preferred Stock · Derivative | 233,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107532 · ownership.xml · derivative · entry 3 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:11 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries A Convertible Preferred Stock · Derivative | 994,069 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107532 · ownership.xml · derivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:11 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionCommon Stock | 102,082 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107532 · ownership.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:02 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock Option (Right to Buy) · Derivative | 15,963 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-106436 · ownership.xml · derivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,963 Underlying: Common Stock · 15,963 shares Expires 2034-09-11 F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 15:43 UTC | Mead Johnson Nutrition Co MJN · Entity 17020 | Disposition to issuerRestricted Stock Units · Derivative | 3,418 | $90.00 | $307,620.00 |
DisclosureSEC source: 0001104659-17-039510 · a4.xml · derivative · entry 3 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,418 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock. F3 · price: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share. F3 · derivative.exercise_date: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share. F3 · derivative.expiration_date: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share. Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 15:43 UTC | Mead Johnson Nutrition Co MJN · Entity 17020 | Disposition to issuerCommon Stock | 27,975 | $90.00 | $2,517,750.00 |
DisclosureSEC source: 0001104659-17-039510 · a4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 2015 Grantor Retained Annuity Trust Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 15:43 UTC | Mead Johnson Nutrition Co MJN · Entity 17020 | Disposition to issuerCommon Stock | 55,244 | $90.00 | $4,971,960.00 |
DisclosureSEC source: 0001104659-17-039510 · a4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 10:14 UTC | Mead Johnson Nutrition Co MJN · Entity 17020 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 4,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016257 · doc4.xml · derivative · entry 5 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,881 shares Expires 2017-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F2 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 10:14 UTC | Mead Johnson Nutrition Co MJN · Entity 17020 | GiftCommon Stock | 4,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016257 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,244 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 10:14 UTC | Mead Johnson Nutrition Co MJN · Entity 17020 | Exercise / conversionCommon Stock | 4,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016257 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 10:14 UTC | Mead Johnson Nutrition Co MJN · Entity 17020 | GrantRestricted Stock Unit (RSU) · Derivative | 3,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016257 · doc4.xml · derivative · entry 4 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,418 Underlying: Common Stock · 3,418 shares Expires 2018-02-28 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. F2 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. Read SEC document |
| March 31, 2015 Filed Apr 2, 2015 21:52 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 387 | $64.50 | $24,961.50 |
DisclosureSEC source: 0000014272-15-000166 · wf-form4_142801155134015.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,851 F1 · shares: Shares awarded to Mr. Cornelius for service as Non-Executive Chairman. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 23:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,654.72 | $60.27 | $159,999.97 |
DisclosureSEC source: 0000014272-15-000046 · wf-form4_142300552285411.xml · derivative · entry 3 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,914.46 Underlying: Common Stock, $0.10 par value · 2,654.72 shares Expires not disclosed F2 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F3 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| January 30, 2015 Filed Feb 3, 2015 23:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GiftCommon Stock, $0.10 par value | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-15-000046 · wf-form4_142300552285411.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,464 Read SEC document |
| January 30, 2015 Filed Feb 3, 2015 23:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 50,000 | $60.60 | $3,029,975.00 |
DisclosureSEC source: 0000014272-15-000046 · wf-form4_142300552285411.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,464 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $60.55 to $60.76, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 31, 2014 Filed Jan 6, 2015 00:38 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 423 | $59.03 | $24,969.69 |
DisclosureSEC source: 0000014272-15-000010 · wf-form4_142050472911497.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,464 F1 · shares: Shares awarded to Mr. Cornelius for service as Non-Executive Chairman. Read SEC document |
| October 15, 2014 Filed Oct 17, 2014 21:16 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 100,000 | $48.92 | $4,892,000.00 |
DisclosureSEC source: 0000014272-14-000248 · wf-form4_141358060439821.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,041 F1 · kind: On July 31, 2014, the reporting person agreed to contribute Bristol-Myers Squibb Company common stock to an exchange fund in exchange for shares of the exchange fund. The exchange fund closed on October 15, 2014 and the shares were contributed on that date. The Bristol-Myers Squibb Company common stock was valued at $48.92 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F1 · price: On July 31, 2014, the reporting person agreed to contribute Bristol-Myers Squibb Company common stock to an exchange fund in exchange for shares of the exchange fund. The exchange fund closed on October 15, 2014 and the shares were contributed on that date. The Bristol-Myers Squibb Company common stock was valued at $48.92 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. Read SEC document |
| September 30, 2014 Filed Oct 2, 2014 20:44 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 488 | $51.18 | $24,975.84 |
DisclosureSEC source: 0000014272-14-000236 · wf-form4_141228268067426.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,041 F1 · shares: Shares awarded to Mr. Cornelius for service as Non-Executive Chairman. Read SEC document |
| June 30, 2014 Filed Jul 2, 2014 22:02 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 515 | $48.51 | $24,982.65 |
DisclosureSEC source: 0000014272-14-000195 · wf-form4_140433853184071.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,553 F1 · shares: Shares awarded to Mr. Cornelius for service as Non-Executive Chairman. Read SEC document |
| March 31, 2014 Filed Apr 2, 2014 11:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 481 | $51.95 | $24,987.95 |
DisclosureSEC source: 0000014272-14-000156 · wf-form4_139643945583184.xml · nonDerivative · entry 3 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,038 F1 · shares: Shares awarded to Mr. Cornelius for service as Non-Executive Chairman. Read SEC document |
| March 13, 2014 Filed Apr 2, 2014 11:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GiftCommon Stock, $0.10 par value | 2,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000156 · wf-form4_139643945583184.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,557 Read SEC document |
| March 13, 2014 Filed Apr 2, 2014 11:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GiftCommon Stock, $0.10 par value | 2,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000156 · wf-form4_139643945583184.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,475 Read SEC document |
| March 05, 2014 Filed Mar 5, 2014 21:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 100,000 | $55.82 | $5,582,000.00 |
DisclosureSEC source: 0000014272-14-000096 · wf-form4_139405562617572.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,393 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $55.71 to $56.06 , inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2014 Filed Feb 4, 2014 22:00 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 100,000 | $48.90 | $4,890,000.00 |
DisclosureSEC source: 0000014272-14-000038 · wf-form4_139155120743543.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,393 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $48.86 to $48.97, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 22:00 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,192 | $50.12 | $159,983.04 |
DisclosureSEC source: 0000014272-14-000038 · wf-form4_139155120743543.xml · derivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,339.53 Underlying: Common Stock, $0.10 par value · 3,192 shares Expires not disclosed F2 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F3 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2013 Filed Jan 2, 2014 21:09 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 470 | $53.15 | $24,980.50 |
DisclosureSEC source: 0000014272-14-000004 · wf-form4_138869693112741.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,393 F1 · shares: Shares awarded to Mr. Cornelius for service as the Non-Executive Chairman. Read SEC document |
| September 30, 2013 Filed Oct 1, 2013 20:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 540 | $46.28 | $24,991.20 |
DisclosureSEC source: 0000014272-13-000011 · wf-form4_138065953593596.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,923 F1 · price: Shares awarded to Mr. Cornelius for service as the Non-Executive Chairman. Read SEC document |
| September 26, 2013 Filed Oct 1, 2013 20:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GiftCommon Stock, $0.10 par value | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-13-000011 · wf-form4_138065953593596.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,383 Read SEC document |
| July 29, 2013 Filed Jul 29, 2013 20:44 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $26.25 | $0.00 |
DisclosureSEC source: 0001225208-13-016850 · doc4.xml · derivative · entry 5 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 2,500 shares Expires 2015-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was May 3, 2005. Read SEC document |
| July 29, 2013 Filed Jul 29, 2013 20:44 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $24.96 | $0.00 |
DisclosureSEC source: 0001225208-13-016850 · doc4.xml · derivative · entry 4 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 2,500 shares Expires 2016-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was May 2, 2006. Read SEC document |
| July 29, 2013 Filed Jul 29, 2013 20:44 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 5,000 | $43.81 | $219,050.00 |
DisclosureSEC source: 0001225208-13-016850 · doc4.xml · nonDerivative · entry 3 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642,383 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.81 to $43.82, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 29, 2013 Filed Jul 29, 2013 20:44 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,500 | $24.96 | $62,400.00 |
DisclosureSEC source: 0001225208-13-016850 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2013 Filed Jul 29, 2013 20:44 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,500 | $26.25 | $65,625.00 |
DisclosureSEC source: 0001225208-13-016850 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2013 Filed Jul 30, 2013 20:34 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 100,000 | $43.92 | $4,392,000.00 |
DisclosureSEC source: 0001225208-13-016914 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,383 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.71 to $44.25, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 30, 2013 Filed Jul 2, 2013 20:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 559 | $44.69 | $24,981.71 |
DisclosureSEC source: 0001225208-13-015460 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642,383 F1 · shares: Shares awarded to Mr. Cornelius for service as the Non-Executive Chairman. Read SEC document |
| May 28, 2013 Filed May 28, 2013 20:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 100,000 | $47.61 | $4,761,000.00 |
DisclosureSEC source: 0001225208-13-013357 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641,824 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.51 to $47.75, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2013 Filed May 20, 2013 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionExecutive Option (right to buy) · Derivative | 205,996 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0001225208-13-012781 · doc4.xml · derivative · entry 5 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock, $0.10 par value · 205,996 shares Expires 2018-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: As Mr. Cornelius had attained age 60, this stock option award vested 100% on the first anniversary of the grant date, which was March 4, 2009. F5 · derivative.expiration_date: As Mr. Cornelius had attained age 60, this stock option award vested 100% on the first anniversary of the grant date, which was March 4, 2009. Read SEC document |
| May 17, 2013 Filed May 20, 2013 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 205,996 | $42.98 | $8,853,708.08 |
DisclosureSEC source: 0001225208-13-012781 · doc4.xml · nonDerivative · entry 4 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,824 F4 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $42.71 to $43.43, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2013 Filed May 20, 2013 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $43.00 | $430,000.00 |
DisclosureSEC source: 0001225208-13-012781 · doc4.xml · nonDerivative · entry 3 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 947,820 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $42.71 to $43.33, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2013 Filed May 20, 2013 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 205,996 | $22.14 | $4,560,751.44 |
DisclosureSEC source: 0001225208-13-012781 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2013 Filed May 20, 2013 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $43.24 | $432,400.00 |
DisclosureSEC source: 0001225208-13-012781 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751,824 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $42.65 to $44.45, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2013 Filed May 9, 2013 20:19 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $39.78 | $397,800.00 |
DisclosureSEC source: 0001225208-13-011831 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.56 to $40.11, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2013 Filed May 9, 2013 20:19 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $39.91 | $399,100.00 |
DisclosureSEC source: 0001225208-13-011831 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.66 to $40.16, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2013 Filed May 2, 2013 21:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $39.85 | $398,500.00 |
DisclosureSEC source: 0001225208-13-011042 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.70 to $40.00, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2013 Filed May 2, 2013 21:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $39.66 | $396,600.00 |
DisclosureSEC source: 0001225208-13-011042 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.25 to $39.81, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 26, 2013 Filed Apr 29, 2013 20:22 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $40.12 | $401,200.00 |
DisclosureSEC source: 0001225208-13-010525 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $39.82 to $40.38, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 20:22 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $40.34 | $403,400.00 |
DisclosureSEC source: 0001225208-13-010525 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 811,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $40.10 to $40.66, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2013 Filed Apr 18, 2013 20:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $40.75 | $407,500.00 |
DisclosureSEC source: 0001225208-13-010117 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $40.57 to $41.06, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 16, 2013 Filed Apr 18, 2013 20:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,000 | $40.82 | $408,200.00 |
DisclosureSEC source: 0001225208-13-010117 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831,824 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $40.60 to $41.08, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.